1. Home
  2. MYGN vs NTLA Comparison

MYGN vs NTLA Comparison

Compare MYGN & NTLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MYGN
  • NTLA
  • Stock Information
  • Founded
  • MYGN 1991
  • NTLA 2014
  • Country
  • MYGN United States
  • NTLA United States
  • Employees
  • MYGN N/A
  • NTLA N/A
  • Industry
  • MYGN Biotechnology: In Vitro & In Vivo Diagnostic Substances
  • NTLA Biotechnology: In Vitro & In Vivo Diagnostic Substances
  • Sector
  • MYGN Health Care
  • NTLA Health Care
  • Exchange
  • MYGN Nasdaq
  • NTLA Nasdaq
  • Market Cap
  • MYGN 2.0B
  • NTLA 1.4B
  • IPO Year
  • MYGN 1995
  • NTLA 2016
  • Fundamental
  • Price
  • MYGN $16.35
  • NTLA $16.45
  • Analyst Decision
  • MYGN Buy
  • NTLA Buy
  • Analyst Count
  • MYGN 12
  • NTLA 17
  • Target Price
  • MYGN $27.64
  • NTLA $57.25
  • AVG Volume (30 Days)
  • MYGN 874.8K
  • NTLA 3.0M
  • Earning Date
  • MYGN 11-07-2024
  • NTLA 11-07-2024
  • Dividend Yield
  • MYGN N/A
  • NTLA N/A
  • EPS Growth
  • MYGN N/A
  • NTLA N/A
  • EPS
  • MYGN N/A
  • NTLA N/A
  • Revenue
  • MYGN $823,600,000.00
  • NTLA $43,086,000.00
  • Revenue This Year
  • MYGN $13.85
  • NTLA $50.73
  • Revenue Next Year
  • MYGN $7.73
  • NTLA $8.69
  • P/E Ratio
  • MYGN N/A
  • NTLA N/A
  • Revenue Growth
  • MYGN 12.15
  • NTLA N/A
  • 52 Week Low
  • MYGN $16.10
  • NTLA $13.95
  • 52 Week High
  • MYGN $29.30
  • NTLA $34.87
  • Technical
  • Relative Strength Index (RSI)
  • MYGN 22.36
  • NTLA 47.20
  • Support Level
  • MYGN $17.12
  • NTLA $15.61
  • Resistance Level
  • MYGN $19.60
  • NTLA $17.83
  • Average True Range (ATR)
  • MYGN 1.09
  • NTLA 1.05
  • MACD
  • MYGN -0.24
  • NTLA 0.25
  • Stochastic Oscillator
  • MYGN 9.08
  • NTLA 77.84

About MYGN Myriad Genetics Inc.

Myriad Genetics is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel with the capability to identify the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm offers biomarker discovery and companion diagnostic services to pharma and biotech companies.

About NTLA Intellia Therapeutics Inc.

Intellia Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.

Share on Social Networks: